Avigen Gains Patent for Producing "Helper-Free" Recombinant AAV
AAV is different than other viruses in that it is incapable of replicating on its own. Cells containing AAV must be co-infected with a "helper virus," typically adenovirus or herpes virus, for AAV itself to replicate—even when manufactured for research or commercial purposes. As such, large-scale manufacturing of AAV required a helper virus, until now
Since adenovirus and herpes viruses are known pathogens that are highly toxic to humans, Avigen scientists identified the small fraction of genetic elements within adenovirus that provide AAV helper functions, allowing AAV vectors to be made free of any contaminating helper viruses. These genetic elements work better than live virus, while completely eliminating the risk of transmitting any pathogenic helper virus.
In December, Avigen was issued U.S. Patent No. 6,001,650, covering genetic constructs and methods for producing recombinant adeno-associated vector (AAV) free of contaminating wild-type AAV virus (see Avigen Receives Patent Covering Wild-Type-Free AAV Production). Using Avigen's patented technology, wild-type AAV cannot be detected, using even the most sensitive techniques currently available.
Avigen Inc. is a biotechnology company involved in the development of gene therapy products derived from adeno-associated virus for the treatment of inherited and acquired diseases. Avigen's proposed gene therapy products are designed for in vivo administration to achieve the production of therapeutic proteins within the body.
For more information: Kenneth G. Chahine, VP of Business Development and Patent Counsel Avigen Inc., 1201 Harbor Bay Pkwy., Ste. 1000, Alameda, CA 94502. Tel: 510-748-7150. Fax: 510-748-7155.